UK health-cost unit backs a Roche cancer drug

UK health-cost unit backs a Roche cancer drug: By Sten Stovall LONDON -(MarketWatch)- The cost regulator for the UK's publicly-funded National Health Service Thursday recommended Roche Holding AG's cancer drug Mabthera as an option when used in combination with a wide range of chemotherapy ...

Top stories of the last 30 days